Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials

What Was Tested

Researchers studied Tirzepatide and GIP (Gastric Inhibitory Polypeptide) in this randomized controlled trial publication.

To evaluate gastrointestinal adverse events (AEs) and the impact of nausea, vomiting or diarrhoea (N/V/D) and any gastrointestinal (GI) AEs overall on weight change with tirzepatide across the SURPASS-1 to -5 clinical trials.

Mediation analyses were conducted to evaluate the contribution of direct and indirect (mediated by N/V/D or GI AEs) effects of tirzepatide on weight change versus comparators.

Who Took Part

This post hoc analysis subdivided participants within each trial into subgroups that self-reported (yes/no) any N/V/D or GI AEs.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

Some participants received a placebo instead of Tirzepatide, giving a reference point.

Change from baseline in body weight at the primary timepoint was assessed within each trial and subgroup.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Diarrhea, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Hypoglycemic Agents, Insulins and Nausea.

The authors tagged it with the keywords GIP and GLP-1 receptor agonist, diarrhoea, gastrointestinal adverse events, incretin therapy, tirzepatide and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Tirzepatide compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.